Celldex Therapeutics Inc. (NASDAQ: CLDX) is 0.68% higher on its value in year-to-date trading and has touched a low of $22.11 and a high of $53.18 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CLDX stock was last observed hovering at around $38.47 in the last trading session, with the day’s gains setting it 1.46%.
Currently trading at $39.93, the stock is 14.62% and 8.78% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.6 million and changing 3.80% at the moment leaves the stock 5.97% off its SMA200. CLDX registered 41.70% gain for a year compared to 6-month loss of -16.92%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 4.78% gain in the last 1 month and extending the period to 3 months gives it a 18.77%, and is 13.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.28% over the week and 5.26% over the month.
Celldex Therapeutics Inc. (CLDX) has around 160 employees, a market worth around $2.65B and $8.30M in sales. Profit margin for the company is -1809.40%. Distance from 52-week low is 80.60% and -24.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.44%).
The EPS is expected to grow by 15.41% this year
268.0 institutions hold shares in Celldex Therapeutics Inc. (CLDX), with institutional investors hold 107.55% of the company’s shares. The shares outstanding are 66.29M, and float is at 64.20M with Short Float at 13.49%. Institutions hold 107.23% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 8.08 million shares valued at $298.89 million. The investor’s holdings represent 13.718 of the CLDX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.83 million shares valued at $289.76 million to account for 13.2988 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.69 million shares representing 7.9679 and valued at over $173.61 million, while VANGUARD GROUP INC holds 6.3512 of the shares totaling 3.74 million with a market value of $138.38 million.
Celldex Therapeutics Inc. (CLDX) Insider Activity
The most recent transaction is an insider sale by Martin Samuel Bates, the company’s SVP AND CFO. SEC filings show that Martin Samuel Bates sold 17,172 shares of the company’s common stock on Jun 14 ’24 at a price of $35.42 per share for a total of $0.61 million. Following the sale, the insider now owns 28125.0 shares.
Celldex Therapeutics Inc. disclosed in a document filed with the SEC on Jun 14 ’24 that Crowley Elizabeth (SR. VP & CPDO) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Jun 14 ’24 and was made at $34.87 per share for $1.05 million. Following the transaction, the insider now directly holds 9074.0 shares of the CLDX stock.
Still, SEC filings show that on Jun 07 ’24, Crowley Elizabeth (SR. VP & CPDO) disposed off 15,000 shares at an average price of $35.06 for $0.53 million. The insider now directly holds 9,074 shares of Celldex Therapeutics Inc. (CLDX).
